Ovarian follicular development during the use of oral contraception: a review - PubMed (original) (raw)

Review

Ovarian follicular development during the use of oral contraception: a review

Angela R Baerwald et al. J Obstet Gynaecol Can. 2004 Jan.

Abstract

Over the past 40 years, alterations to the composition of oral contraceptives (OCs) have been made in attempts to reduce adverse effects and to improve patient compliance while maintaining contraceptive efficacy. However, there is growing evidence to indicate that reducing the estrogen dose to minimize adverse effects may have compromised the degree of hypothalamo-pituitary-ovarian suppression, particularly during the hormone-free interval (HFI) or following missed doses. Follicle development during OC use appears to occur in association with a loss of endocrine suppression during the HFI. This information provides a rationale for reducing or eliminating the HFI in OC regimens. There is also evidence for an increased risk of follicle development and ovulation in women who use delayed OC initiation schemes, such as the "Sunday Start" method. It is not currently known why some follicles ovulate during OC use while others regress or form anovulatory follicle cysts. Continued research about follicle development during OC use would provide insight into understanding the precise mechanisms of action underlying combined OCs, as well as those of continuous OC formulations and emergency contraceptive regimens.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Dr Pierson has received grants from Janssen-Ortho Inc., Organon NV, RW Johnson Pharmaceutical Research Institute, and Ares-Serono.

Similar articles

• The mechanism of action of a new low-dosed combined oral contraceptive.
  Dericks-Tan JS, Schneider K, Taubert HD. Dericks-Tan JS, et al. Arch Gynecol. 1980;229(2):107-14. doi: 10.1007/BF02109949. Arch Gynecol. 1980. PMID: 6768343
• Ovarian follicular dynamics during conventional vs. continuous oral contraceptive use.
  Birtch RL, Olatunbosun OA, Pierson RA. Birtch RL, et al. Contraception. 2006 Mar;73(3):235-43. doi: 10.1016/j.contraception.2005.09.009. Epub 2005 Nov 2. Contraception. 2006. PMID: 16472562 Clinical Trial.
• A regimen of oral contraceptives restricted to the periovulatory period may permit folliculogenesis but inhibit ovulation.
  Letterie GS. Letterie GS. Contraception. 1998 Jan;57(1):39-44. doi: 10.1016/s0010-7824(97)00205-9. Contraception. 1998. PMID: 9554249 Clinical Trial.
• Rationale for eliminating the hormone-free interval in modern oral contraceptives.
  London A, Jensen JT. London A, et al. Int J Gynaecol Obstet. 2016 Jul;134(1):8-12. doi: 10.1016/j.ijgo.2015.10.028. Epub 2016 Mar 20. Int J Gynaecol Obstet. 2016. PMID: 27067074 Review.
• Why do inadvertent pregnancies occur in oral contraceptive users? Effectiveness of oral contraceptive regimens and interfering factors.
  Fraser IS, Jansen RP. Fraser IS, et al. Contraception. 1983 Jun;27(6):531-51. doi: 10.1016/0010-7824(83)90019-7. Contraception. 1983. PMID: 6413129 Review.

Cited by

• Evaluation of texture features for analysis of ovarian follicular development.
  Bian N, Eramian MG, Pierson RA. Bian N, et al. Med Image Comput Comput Assist Interv. 2006;9(Pt 2):93-100. doi: 10.1007/11866763_12. Med Image Comput Comput Assist Interv. 2006. PMID: 17354760 Free PMC article.
• Pharmacokinetic drug-drug interaction between ethinyl estradiol and gestodene, administered as a transdermal fertility control patch, and two CYP3A4 inhibitors and a CYP3A4 substrate.
  Winkler J, Goldammer M, Ludwig M, Rohde B, Zurth C. Winkler J, et al. Eur J Drug Metab Pharmacokinet. 2015 Dec;40(4):389-99. doi: 10.1007/s13318-014-0215-8. Epub 2014 Jul 6. Eur J Drug Metab Pharmacokinet. 2015. PMID: 24997757 Clinical Trial.
• The Role of Dydrogesterone in the Management of Luteal Phase Defect: A Comprehensive Review.
  Muneeba S Jr, Acharya N, Mohammad S. Muneeba S Jr, et al. Cureus. 2023 Nov 3;15(11):e48194. doi: 10.7759/cureus.48194. eCollection 2023 Nov. Cureus. 2023. PMID: 38050524 Free PMC article. Review.
• U.S. Selected Practice Recommendations for Contraceptive Use, 2024.
  Curtis KM, Nguyen AT, Tepper NK, Zapata LB, Snyder EM, Hatfield-Timajchy K, Kortsmit K, Cohen MA, Whiteman MK; Contributors. Curtis KM, et al. MMWR Recomm Rep. 2024 Aug 8;73(3):1-77. doi: 10.15585/mmwr.rr7303a1. MMWR Recomm Rep. 2024. PMID: 39106301 Free PMC article.
• Hormone-based models for comparing menstrual cycle and hormonal contraceptive effects on human resting-state functional connectivity.
  Casto KV, Jordan T, Petersen N. Casto KV, et al. Front Neuroendocrinol. 2022 Oct;67:101036. doi: 10.1016/j.yfrne.2022.101036. Epub 2022 Sep 17. Front Neuroendocrinol. 2022. PMID: 36126748 Free PMC article.

References

1. 1. Pincus G, Rock J, Garcia C. Fertility control with oral medication. Am J Obstet Gynecol. 1958;75:1333–46. - PubMed
2. 1. Wan LS, Ganguly M, Weiss G. Pituitary response to LHRH stimulation in women on oral contraceptives: a followup dose response study. Contraception. 1981;24:229–34. - PubMed
3. 1. Tafurt CA, Sobrevilla LA, de Estrada R. Effects of progestin-estrogen combination and progestational contraceptives on pituitary gonadotropins, gonadal steroids and sex hormone-binding globulin. Fertil Steril. 1980;33:261–6. - PubMed
4. 1. Barnhart K, Devoto L, Pommer R, Sir-Pettermann T, Robinovic J, Coutinho E. Neuroendocrine mechanism of anovulation in users of contraceptive subdermal implant of nomegestrol acetate (uniplant) Fertil Steril. 1997;67:250–5. - PubMed
5. 1. Van Heusden AM, Killick SR, Coelingh Bennink HJ, Fauser BC. Single monthly administration of the anti-progestagen org 31710 in users of the 75 microg desogestrel progestagen-only pill: effects on pituitary-ovarian activity. Hum Reprod. 2000;15:629–36. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Europe PubMed Central
  • PubMed Central

• Miscellaneous

  • NCI CPTAC Assay Portal